In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

A number of equities research analysts have issued reports on GMED shares. Bank of America upgraded Globus Medical from an “underperform” rating to a “neutral” rating and boosted their ...

Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...

Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share.

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...

The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth. Montgomery County's Globus Medical has agreed to acquire a California life ...

Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...